Because CDK1, CDK2, and XIAP are overexpressed in ACC, the combination of flavopiridol and carfilzomib is an appropriate treatment strategy that targets commonly dysregulated proteins in ACC. Here, CDK2 is linked to adrenal cortex carcinoma.